These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34252986)

  • 21. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
    Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
    Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Jauw YW; Zijlstra JM; de Jong D; Vugts DJ; Zweegman S; Hoekstra OS; van Dongen GA; Huisman MC
    PLoS One; 2017; 12(1):e0169828. PubMed ID: 28060891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
    Islam S; Qi W; Morales C; Cooke L; Spier C; Weterings E; Mahadevan D
    Mol Cancer Ther; 2017 Oct; 16(10):2083-2093. PubMed ID: 28615297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
    Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
    J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab.
    Zhang L; Zhou S; Zhou T; Li X; Tang J
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33887878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma.
    Zou L; Song G; Gu S; Kong L; Sun S; Yang L; Cho WC
    Curr Cancer Drug Targets; 2019; 19(9):681-687. PubMed ID: 31142246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
    Wang L; Wang W; Li X; Guo Y; Zhu X
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.
    Chiche J; Reverso-Meinietti J; Mouchotte A; Rubio-Patiño C; Mhaidly R; Villa E; Bossowski JP; Proics E; Grima-Reyes M; Paquet A; Fragaki K; Marchetti S; Briere J; Ambrosetti D; Michiels JF; Molina TJ; Copie-Bergman C; Lehmann-Che J; Peyrottes I; Peyrade F; de Kerviler E; Taillan B; Garnier G; Verhoeyen E; Paquis-Flucklinger V; Shintu L; Delwail V; Delpech-Debiais C; Delarue R; Bosly A; Petrella T; Brisou G; Nadel B; Barbry P; Mounier N; Thieblemont C; Ricci JE
    Cell Metab; 2019 Jun; 29(6):1243-1257.e10. PubMed ID: 30827861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
    Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
    Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
    Hayashi K; Nagasaki E; Kan S; Ito M; Kamata Y; Homma S; Aiba K
    Cancer Sci; 2016 May; 107(5):682-9. PubMed ID: 26920337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
    J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.
    Rushton CK; Arthur SE; Alcaide M; Cheung M; Jiang A; Coyle KM; Cleary KLS; Thomas N; Hilton LK; Michaud N; Daigle S; Davidson J; Bushell K; Yu S; Rys RN; Jain M; Shepherd L; Marra MA; Kuruvilla J; Crump M; Mann K; Assouline S; Connors JM; Steidl C; Cragg MS; Scott DW; Johnson NA; Morin RD
    Blood Adv; 2020 Jul; 4(13):2886-2898. PubMed ID: 32589730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.
    Tomita A
    J Clin Exp Hematop; 2016; 56(2):89-99. PubMed ID: 27980307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.